PUMA BIOTECHNOLOGY,

PBYI
Real-time Estimate Cboe BZX - 10:27 2022-12-02 am EST
4.600 USD +0.88%

Puma Biotechnology Licenses Global Rights to Takeda's Cancer Therapy Alisertib

09/20/2022 | 04:23pm
(MT Newswires) -- Puma Biotechnology (PBYI) said late Tuesday that it has entered into an agreement with Japan's Takeda to license the global rights to alisertib, an investigational cancer therapy.

Puma will be solely responsible for alisertib's worldwide development and commercialization. Takeda will receive $7 million up front and is eligible to get sales-based royalty payments and up to $287.3 million in potential future milestone payments tied to Puma's achievement of certain regulatory and commercial goals.

Puma will initially focus on developing alisertib for the treatment of breast cancer subtypes and small cell lung cancer, the company said.

Price: 2.45, Change: -0.04, Percent Change: -1.61

MT Newswires 2022
Copier lien
All news about PUMA BIOTECHNOLOGY, INC.
11/11
11/10
11/03
11/03
11/03